Doxil and Gemcitabine in Recurrent Ovarian Cancer
Standard treatment for recurrent ovarian cancer is chemotherapy with one or more drugs. One of these drugs, Doxil, can cause skin toxicity at the standard dosages. This study investigates using a lower dose given more frequently in combination with a second drug Gemcitabine.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||A Phase II Study of Every 2 Week Doxil and Gemcitabine in Recurrent Ovarian Cancer|
- rate of hand-foot syndrome
- objective response rate
|Study Start Date:||April 2006|
This study will evaluate the toxicities of Doxil and Gemcitabine given on an every two week basis. Our hypothesis is that toxicity will be less than that with standard dosing without any negative effect on survival. Patients will also be evaluated with CT scans every 3 months. Toxicity will be assessed with every cycle of treatment. Treatment will continue until toxicity or signs of progression.
|United States, Rhode Island|
|Women and Infants' Hospital|
|Providence, Rhode Island, United States, 02905|
|Principal Investigator:||Paul A DiSilvestro, MD||Program in Women's Oncology|